Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BeOne
Biotech
BeOne shelves 5 cancer programs, halts ph. 2 arthritis trial
Four of the five cancer assets have been discontinued entirely, and the company is currently determining next steps for the arthritis candidate.
Darren Incorvaia
May 7, 2026 11:15am
BeOne signs $2B deal for option on preclinical trispecific
Apr 30, 2026 7:55am
Jefferies London conference earns reputation as 'JPM for Europe'
Nov 18, 2025 10:00am
Fierce Pharma
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
Oct 19, 2025 10:45am
BeOne asset hits primary endpoint, tees up blood cancer filings
Aug 29, 2025 9:50am
Pfizer’s reputation wrangler plans departure—Chutes & Ladders
Jul 11, 2025 8:30am
